Passwords on the Rise Despite Evidence That They Are Increasingly Unable to Protect, Finds Thales
6.5.2020 09:00:00 EEST | Business Wire | Press release
According to the 2020 Thales Access Management Index – Europe and Middle East Edition 1 – nearly a third (29%) of organisations in Europe and the Middle East still see usernames and passwords as one of the most effective means to protect access to their IT infrastructure, two years after the inventor of the complex static password admitted they don’t work. In fact, 67% of respondents indicate that their organisations plan to expand its use of usernames and passwords in the future. This continued reliance on outdated security comes despite IT leaders revealing it is increasingly easier (48%) to sell the need for security to their boards compared to last year (29%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005035/en/
(Photo: Thales)
Surveying 400 IT decision-makers across Europe and the Middle East, Thales’s new research found that the majority (57%) of IT professionals revealed that unprotected infrastructure is one of the biggest targets for cyber-attacks. Therefore any organization utilising it, as a result of business pressure driving them to adopt digital transformation technologies, are likely to be putting themselves at a higher level of risk.
Solving the Security vs. Convenience Conundrum
With the Covid-19 global pandemic causing many companies to work from home, IT departments are battling to provide employees with both security and convenience. In fact, over two-thirds (67%) of European IT leaders say their security teams feel under pressure to provide convenient access to applications and cloud services for users, but still maintain security – an indication they’re struggling to balance their digital transformation and security priorities. To this end, 96% believe that strong authentication and access management solutions can facilitate secure cloud adoption. Over three-quarters (76%) also revealed employee authentication needs to be able to support secure access to a broad range of services including virtual private networks and cloud applications.
Making small improvements
While some organisations still rely on legacy authentication methods like usernames and passwords, growing awareness of the threats is prompting action with almost all (94%) organizations having changed their security policies around access management in the last 12 months. Staff training on security and access management (47%), increasing spend on access management (43%), and access management becoming a board priority (37%), have all seen an increased focus. This is set to pay off in compliance terms too, with nearly all (98%) European respondents admitting controlling who has access to their company’s data. This will help them meet data regulation requirements like GDPR.
“As more and more businesses move to adopt cloud-based services for CRM, email, employee collaboration and IT infrastructure as part of their digital transformation strategies, the struggle to extend old solutions, designed to protect internal resources, to the outside world becomes very problematic. Often, in an effort to adapt to the new working habits of users connecting from anywhere, which is increasingly pertinent right now and will become standard moving forward, businesses tend to revert back to old password-based logins for cloud services in despair. This is knowingly increasing their security exposure to credential stuffing and phishing attacks,” said Francois Lasnier, Vice President for Access Management solutions at Thales.
Two steps forward, one step back
Looking ahead, some IT leaders are set to potentially use their influence at board level more wisely, with investment in the use of more secure methods such as biometric authentication (75%) and smart SSO (81%) set to increase in the next year. However, a third (67%) still plan to expand their use of usernames and passwords, which is a similar size to those intending to further utilise passwordless authentication methods (70%).
“For a long time, the biggest battle IT leaders have faced is increasing board awareness around taking the threat of security seriously,” Lasnier continued. “Now that they have that buy in, the focus should be on highlighting the importance access management plays in implementing a zero trust security policy to their executive management. With this in place, risk management professionals will be able to put in place a ‘Protect Everywhere - Trust Nobody’ approach as they expand in the cloud.”
1 The 2020 Access Management Index, is a survey of 400 executives in 7 countries in Europe and the Middle East with responsibility for, or influence over, IT and data security. The survey, reporting and analysis was conducted by Vanson Bourne , commissioned by Thales.
About Thales
Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €18.4 billion in 2019.
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.
PLEASE VISIT
Thales Group
Security
Download HD photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005035/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Security
Constance Arnoux
+33 (0)1 57 77 91 58
constance.arnoux@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
